Stratos Wealth Partners LTD. Has $8.83 Million Stock Position in Amgen Inc. $AMGN

Stratos Wealth Partners LTD. raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 10.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 31,290 shares of the medical research company’s stock after purchasing an additional 3,045 shares during the period. Stratos Wealth Partners LTD.’s holdings in Amgen were worth $8,830,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Amgen by 1.6% in the second quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after buying an additional 841,117 shares during the period. State Street Corp grew its holdings in Amgen by 0.6% in the second quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock worth $8,196,775,000 after purchasing an additional 177,035 shares during the period. Geode Capital Management LLC increased its stake in Amgen by 2.3% in the second quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company’s stock valued at $3,619,489,000 after purchasing an additional 291,271 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Amgen by 5.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after purchasing an additional 687,735 shares during the period. Finally, Laurel Wealth Advisors LLC boosted its position in shares of Amgen by 27,765.8% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after purchasing an additional 6,676,575 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $366.58 on Thursday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The stock has a market cap of $197.40 billion, a PE ratio of 25.76, a price-to-earnings-growth ratio of 3.73 and a beta of 0.46. The stock’s fifty day simple moving average is $336.16 and its two-hundred day simple moving average is $312.77. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $385.12.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be paid a $2.52 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a yield of 2.7%. Amgen’s dividend payout ratio (DPR) is 66.90%.

Wall Street Analyst Weigh In

A number of analysts recently commented on AMGN shares. Cantor Fitzgerald boosted their target price on Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. TD Cowen restated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Citigroup upped their target price on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. HSBC reissued a “buy” rating and issued a $425.00 price target on shares of Amgen in a research report on Wednesday, December 10th. Finally, Wells Fargo & Company upped their price objective on shares of Amgen from $300.00 to $325.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and an average target price of $354.04.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Daiwa raised its price target to $410 and kept an “outperform” rating, signaling meaningful upside versus recent levels. Daiwa target raise
• Positive Sentiment: Fundamental tailwinds: Amgen recently beat EPS and revenue expectations and set FY2026 EPS guidance (21.60–23.00), which supports near-term confidence in earnings power and helped lift sentiment. (Company earnings release)
• Neutral Sentiment: Zacks published a momentum-themed piece highlighting AMGN as a top-ranked momentum stock — useful for momentum investors but not a direct catalyst. Zacks momentum article
• Neutral Sentiment: Brokerage consensus remains constructive (reported as “Moderate Buy”), which is supportive but largely confirms existing analyst views. Consensus rating
• Neutral Sentiment: Amgen will trade ex-dividend in two days — a routine liquidity/event timing item that can briefly affect intraday moves but is not a fundamental change. Ex-dividend notice
• Neutral Sentiment: Recent short-interest reports show zero shares and NaN changes — this appears to be erroneous or non-actionable data, so it shouldn’t be driving meaningful market moves today.
• Negative Sentiment: Mizuho raised its target from $280 to $295 but that target still implies a material downside relative to recent market levels, which could temper upside expectations despite the upgrade. Mizuho target note

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This trade represents a 30.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.76% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.